CML

conference reporter

by Michael J. Mauro, MD

At the 64th ASH Annual Meeting and Exposition, researchers continued to explore new ways to optimize the treatment of chronic phase chronic myeloid......READ MORE

conference reporter

by Neil P. Shah, MD, PhD

Although great progress has been made in the treatment of chronic phase chronic myeloid leukemia (CML), many patients still experience intolerance ......READ MORE

conference reporter

by Neil P. Shah, MD, PhD

At the 64th ASH Annual Meeting and Exposition, emerging data underscored the importance of tyrosine kinase inhibitor (TKI) tolerability and dose op......READ MORE

conference reporter

by Hagop M. Kantarjian, MD

The treatment of chronic phase chronic myeloid leukemia (CML) is evolving in response to newer data on BCR::ABL1 tyrosine kinase inhibitors (TKIs).......READ MORE

conference reporter

by Hagop M. Kantarjian, MD

At the 64th ASH Annual Meeting and Exposition, emerging data on the treatment of chronic phase chronic myeloid leukemia (CML) continued to add to t......READ MORE